These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30151728)

  • 81. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Mannucci E
    Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.
    Kim GS; Park JH; Won JC
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):106-116. PubMed ID: 31099200
    [TBL] [Abstract][Full Text] [Related]  

  • 83. New Therapeutic Strategies for Type 2 Diabetes
    Yehya A; Sadhu AR
    Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Gliptins - do they increase cardiovascular risk or benefit?
    Doggrell SA; Dimmitt SB
    Expert Opin Drug Saf; 2014 May; 13(5):675-80. PubMed ID: 24684173
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cardiovascular Outcomes of New Medications for Type 2 Diabetes.
    Trujillo JM; Wettergreen SA; Nuffer WA; Ellis SL; McDermott MT
    Diabetes Technol Ther; 2016 Dec; 18(12):749-758. PubMed ID: 27835045
    [TBL] [Abstract][Full Text] [Related]  

  • 88. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical implications of cardiovascular outcome trials in type 2 diabetes.
    Mellbin LG; Wang A; Rydén L
    Herz; 2019 May; 44(3):192-202. PubMed ID: 30805659
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Analysis of cardiovascular safety of novel glucose-lowering medications].
    Mkrtumyan AM; Markova TN; Mishchenko NK
    Kardiologiia; 2019 Jul; 59(7):76-83. PubMed ID: 31322093
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
    Dawwas GK; Smith SM; Park H
    Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effect of glucose-lowering therapies on heart failure.
    Nassif M; Kosiborod M
    Nat Rev Cardiol; 2018 May; 15(5):282-291. PubMed ID: 29368701
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.
    Yang DY; He X; Liang HW; Zhang SZ; Zhong XB; Luo CF; Du ZM; He JG; Zhuang XD; Liao XX
    Cardiovasc Diabetol; 2019 Apr; 18(1):47. PubMed ID: 30961600
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Treatment of diabetes and heart failure: a paradigm shift for cardiologists?
    Brochu B; Chan M
    Curr Opin Cardiol; 2019 Mar; 34(2):207-212. PubMed ID: 30608252
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Impact of empagliflozin in patients with diabetes and heart failure.
    Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
    Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 98. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials.
    Malik AH; Yandrapalli S; Goldberg M; Jain D; Frishman WH; Aronow WS
    Cardiol Rev; 2020; 28(3):116-124. PubMed ID: 31868769
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
    Testani JM; Inzucchi SE; Voors AA
    Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.